Purdue Pharma signs guilty plea, preps $8B+ settlement on Oxy controversy — report; Flagship brings in a comms chief
Purdue Pharma may soon be signing off on a guilty plea and an $8 billion-plus settlement to wrap up its controversial role distributing OxyContin.
The AP has the breaking story this morning.
Purdue filed for bankruptcy last year, along with Insys and followed by Mallinckrodt, as it navigated its way through a blizzard of litigation surrounding Oxy, which triggered an epidemic of abuse around the country.
Flagship Pioneering pipes new comms chief on board
Flagship Pioneering has recruited a new chief of communications, and they’re bringing her in as a senior partner.
Christine Heenan, president and founder of the Clarendon Group, was tapped for the post at the big biotech VC, which specializes in spinning out ambitious biotechs with grand visions and the bank account to back it up.
She’s being brought on “to shape the organization’s global brand strategy, communications and external affairs,” according to Flagship. And she will report directly to the head honcho himself, Noubar Afeyan.
Ascentage burnishes cancer drug prospects as Chinese regulators put olverembatinib in the fast lane
Ascentage Pharma has won a priority review from Chinese regulators for its drug treating chronic myeloid leukemia.
The drug is olverembatinib (or HQP1351), which the company describes as the first third-generation BCR-ABL inhibitor in China.
Yifan Zhai, the CMO at Ascentage Pharma, noted: “This priority review granted to olverembatinib will help expedite the approval process, hopefully soon changing the current treatment options for patients with CML in China who cannot be effectively treated by currently available TKIs. We hope olverembatinib will soon be approved to benefit more patients.”